Adma Biologics (ADMA) Net Equity Issued and Repurchased (2012 - 2022)

Adma Biologics (ADMA) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $64.6 million in Q4 2022.

• Quarterly Net Equity Issued and Repurchased rose 20.09% year-over-year to $64.6 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $64.6 million (down 46.64% YoY) and the FY2022 annual result came in at $64.6 million, down 46.64% from the prior year.
• Net Equity Issued and Repurchased improved to $64.6 million in Q4 2022, from $53.8 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $88.7 million in Q1 2020 to a low of -$1280.0 in Q3 2018.
• A 5-year average of $36.5 million and a median of $36.9 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 68.99% in 2021, down 52.75% in 2021.
• Tracing ADMA's Net Equity Issued and Repurchased over 5 years: stood at -$1280.0 in 2018, then jumped by 3781122.5% to $48.4 million in 2019, then plunged by 34.19% to $31.9 million in 2020, then surged by 68.99% to $53.8 million in 2021, then climbed by 20.09% to $64.6 million in 2022.
• The last three Net Equity Issued and Repurchased figures came in at $64.6 million (Q4 2022), $53.8 million (Q4 2021), and $8.2 million (Q3 2021), per Business Quant data.